



AVICANNA™

Q2 2024

An International Biopharmaceutical Strategy

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments

TSX: AVCN

OTCQX: AVCNF

FSE: ONN

avicanna.com

Forward-Looking Statements

Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations and other applicable securities laws ("forward-looking statements"). Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements and information about anticipated dates for revenue recognition; business strategy, product development, timing of product development, events and courses of action, anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical studies/trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates, and beliefs at the they are made. Forward-looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna may operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these forward-looking statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance, or achievements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely impact our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for our products; the demand and pricing of cannabis and cannabidiol ("CBD"); security threats, including a loss/theft of proprietary technology; our relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; our dependence on key personnel; the severity, duration and effects of the pandemic related to COVID19 on our business, and additional risk factors included elsewhere in Avicanna's public disclosure record, including, without limitation, under the heading "Risk Factors" in its annual information form dated April 1st, 2024 and final short form prospectus dated November 27, 2020, in each case filed with the Canadian securities regulators and available under Avicanna's profile on SEDAR at www.sedar.com.

Although Avicanna has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Avicanna is an early-stage company with a short operating history, and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna's expectations include, consumer sentiment towards Avicanna's products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and CBD, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counterparties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, unexpected delays in the commercialization of products and the severity, duration and effects of COVID19. Forward-looking statements contained in this presentation are as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Financial Information and Management Estimates

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein.

Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of management. Management believes that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete.

Third Party Information

Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Where this presentation quotes any information or data from any third-party source, it should not be interpreted that Avicanna has adopted or endorsed such information or data as being accurate. Avicanna has not independently verified any of such information from third-party sources or any underlying assumptions. Accordingly, Avicanna makes no representation or warranty (express or implied) on the fairness, accuracy, completeness or correctness of any such third-party information.

Disclaimer

No securities commission or similar authority of Canada, the United States or any other jurisdiction has reviewed or in any way passed upon this presentation, and any representation to the contrary is an offence. Readers should not construe the contents of this presentation as investment, legal, tax, regulatory, financial or accounting advice and are urged to consult with their own advisers in relation to such matters.



0.1 Corporate Highlights

An International Medical and Biopharmaceutical Strategy

Commercial Platform

- 4 commercial stage business pillars
- 30+ commercialized proprietary SKUs
- First pharmaceutical marketing authorization (Trunerox)
- Addressing a global market opportunity – 20+ countries
- 2023 revenue of \$16.8M, representing 314% growth year over year

Scientific Platform

- Established industry leading R&D and scientific infrastructure
- Research and clinical partnerships with leading academic and clinical institutions
- Proprietary and indication specific pharmaceutical pipeline
- Medical affairs and clinical development platform
- JLABS @Johnson and Johnson incubated – at MaRS

Q1 2024 Financial Highlights



450%
Y-Y revenue
growth



\$6.45M
Record Revenue



51%
Record Gross Margins




**1st Adjusted
EBIDTA** positive
quarter



Positive cash
from operations



0.2 Timeline and Evolution



1.0 Commercial Business Pillars

1.1



Medical Cannabis
Products

1.2



Medical Cannabis Care
Platform*

1.3



Pharmaceutical
Products

1.4



Active Pharmaceutical
Ingredients



1.1 RHO Phyto

Advanced Drug Delivery System Formulations
(CBD, THC, CBG) - for International Medical
Market Segments



1.1.1 Canadian Commercialization Infrastructure

Proprietary and Commercial SKUs Across 133 Commercial Listings*



*As of December 2023



Established through the acquisition of



“We are grateful for the trust placed in us by our medical cannabis patients over the past few years, and are confident we’ve found the right partner in Avicanna to continue to support them. As we move away from medical cannabis distribution, we remain firm in our belief that this medication should be dispensed in pharmacies like all others and will continue our advocacy to that end.”

- Jeff Leger, President, Shoppers Drug Mart

1.2
MyMedi.ca

A Complete Medical Cannabis
Care Platform



MyMedi.ca

MEDICAL CANNABIS CARE

1.2.1 MyMedi.ca

Online Platform for Canadian Patients and the Medical Community

- Evidence-driven medical cannabis formulary - with 200+ SKUs from over 35 brands
- Pharmacist-led and bilingual patient support programs
- Specialty care programs including compassionate pricing and Veterans' affairs
- 30 Avicanna SKUs including the complete RHO Phyto formulary
- Insurance coverage and adjudication through 17 private and public payers in Canada
 - 75%+ revenue from insurance coverage



72% of patients would consider using medical cannabis if recommended by their oncologist/family doctor*



Pharmacist-led interventions led to favorable effects on drug-related problems and increased adherence to medication regimens, leading to reduction in healthcare costs**

*Sunnybrook cancer centre pilot study on medical cannabis

**Bou Malham C, El Khatib S, Cestac P, Andrieu S, Rouch L, Salameh P. Impact of pharmacist-led interventions on patient care in ambulatory care settings: A systematic review. Int J Clin Pract. 2021 Nov;75(11):e14864. doi: 10.1111/ijcp.14864. Epub 2021 Sep 20. PMID: 34523204.






1.2.2 Medical Affairs, Education and Training



Patients

- Education on the potential benefits and risks associated with medical cannabis
- Pharmacist led dosing and product support
- Harm reduction education and initiatives



Health Care Providers

- Training and product guidelines on dosing and titration based on the highest-level of evidence
- Educational modules and courses including:
 - Avicenna Academy
 - CCIC's accredited Cannabis Syllabus

 <p>AVICENNA ACADEMY</p>	 <p>CCIC Canadian Consortium for the Investigation of Cannabinoids</p>
<ul style="list-style-type: none"> • Introduction to Cannabinoid based medicine • Practical & Clinical consideration for the prescriptions of cannabinoid based medicine • Case Study Based Learning • Understanding RHO Phyto Portfolio 	<ul style="list-style-type: none"> • Introduction to the Endocannabinoid System Cannabis Basics • Cannabis Use Disorder • Acute Adverse Effects, Drug interactions and Contraindications of Cannabis • Cannabis Policy in Canada



1.3 Pharmaceutical Products and Pipeline

A Complete Medical Cannabis Platform





1.3.2 Pharmaceutical Pipeline and Drug Candidates

Designed to Address 5 Major Clinical Areas



Sleep



Eczema/
Epidermolysis Bullosa



Pain
Management



Anxiety &
Depression



Epilepsy

- Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage.
- Leveraging the company's scientific platform and vertical integration to deliver proprietary and accessible finished products.

Drug Candidate	Target	Status	Next Steps	Delivery
Trunerox™	(LGS) and (DS) Syndromes	Approved INVIMA, Colombia	Claim Expansion and Registration in LATAM	Oral
AVCN583601	Epidermolysis Bullosa	RWET Completed	Phase II Planning Stage	Topical
AVCN467504	MSK Pain	RWET Completed	Phase II Planning Stage	Topical
AVCN319301a & AVCN319301b	Arthritis	GMP Pilot Completed	Phase II Approval Stage	Oral



1.3.3 Pharmaceutical Candidates with Completed RWE Results




3% CBD Local Cream Epidermolysis Bullosa

- Study led by Dr. Elena Pope, Head of Dermatology at the Hospital for Sick Children, Toronto Canada.
- The retrospective cohort study evaluated wound healing, pain, and itch end points.
- The study enrolled 20 patients with various subtypes of epidermolysis bullosa including dystrophic (60%), simplex (30%) and junctional (10%).
- After one month, 55% of patient reported improvements in wound healing while 45% displayed wound stability.
- Evaluation of self-reported itch and pain scores were reported and of study participants evaluated, 45% continued to use treatment over 6 months.

2% CBD – 1 % CBG Deep Tissue Gel MSK Pain

- Study led by Sante Cannabis on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, localized pain, and post-surgical pain
- Seventy-one participants completed baseline testing and 1 months follow up including medical history, medication use and two standardized symptom questionnaires.
- The RWE study participants with an average age of 58 ± 15 (64% women) all presented with symptoms of chronic pain.
- 35.4% improvement in health-related domains including symptoms, physical functioning, physical well-being, and confidence to manage symptoms.





1.3.1 Trunerox™ 10% CBD Oral Solution

Adjunctive Treatment of Seizures Associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS)

- Marketing authorization obtained in Colombia by INVIMA Q1 2024
- Expected commercialization in Colombia late 2024 with opportunities to expand into other South and Central American markets
- Proprietary formulation manufactured under GMP standards and utilizing the company's purified API
- Launching 2H 2024

Prevalence Data

- Around 50 million people worldwide have epilepsy, one of the most common neurological diseases globally¹
 - High income countries: 49 per 100,000
 - Low-income and middle-income countries: 139 per 100,000
- Despite the availability of 28 FDA approved antiepileptic drugs nearly 40% of individuals lack seizure control²
- Prevalence to the action indication is nearly 10% of all pediatric epilepsy cases

1. Burden of epilepsy in Latin America and The Caribbean: a trend analysis of the Global Burden of Disease Study 1990 – 2019 Kevin Pacheco-Barrios,a,b,c,y* Alba Navarro-Flores,d,y Alejandra Cardenas-Rojas,b,y Paulo S. de Melo,b Elif Uygur-Kucukseymen,b,h Carlos Alva-Diaz, M.D.,e,i Felipe Fregni,b,f and Jorge G. Burneo

2. World Health Organization. (2024, February 7). Epilepsy Fact Sheet. <https://www.who.int/news-room/fact-sheets/detail/epilepsy>



Sanitary registration
No. INVIMA 2024M-0021290



1.4
Active Pharmaceutical Ingredients
(Aureus Santa Marta™)



AUREUS
SANTA MARTA

1.4.1 Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Avicanna's Supply Chain Business Segment and Vertical Integration

Raw Material Business Unit and Brand



- 3 international pharmaceutical marketing authorizations with Aureus API including Trunerox™
- Avicanna's **low cost and consistent** supply of cannabinoids for its finished products through **in-house cultivation and extraction**
- Providing the pharmaceutical partners with active pharmaceutical ingredients (API) with completed exports into **17 international markets**



Established, Sustainable and Economical Cultivation and Extraction Infrastructure



- Majority owned subsidiary in Santa Marta Colombia with **300,000 square feet and 26,000 kg of annual capacity**
- **USDA National Organic Program certified** and GACP certification
- 30+ completed harvest validating **below 10 cents per gram cost**
- Cultivating commercial crops of **CBD, CBG, THC and feminized seeds** since 2020



1.5 Avicanna Around the World


Global Operations and Exports - 20+ Countries



MyMedi.ca
MEDICAL CANNABIS CARE



TRUNEROX™





2.0 Scientific Platform

R&D Platform Delivering Advanced and
Evidence-Based Cannabinoid Products

2.1 Established Scientific Platform



30+ Proprietary
Commercial Products



10+ Scientists



Extensive Pharmaceutical
Pipeline



7 Pending
Patents



11 Canadian Government Research
Grants Awarded Since 2020



100% Ownership of
All IP and Trade Secrets



2.2 World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada's Leading Institutions Since 2017



3.0 Financial Overview



AVICANNA™

3.1 Financial & Capital Overview


Highlights

Q1 2024

- Record revenue of \$6.45M
- First EBIDTA positive quarter in company history
- Consolidated gross margin of 51%

2023

- Revenue of \$16.8M, growth of 314% from \$4M in 2022
- \$6.67M consolidated gross profit, an increase of more than 500% from 2022



TSX: AVCN

R&D and Pharmaceutical issuer on the TSX senior exchange since IPO in 2019

OTC QX

BÖRSE
FRANKFURT

OTCQX: AVCNF

FSE: ONN



3.2 Management and Board of Directors

Senior Management Team

Aras Azadian
Founder and CEO

Phillip Cardella
Chief Financial Officer

Stephen Kim
Chief Legal Officer & General Counsel

Ivana Marić
Executive Vice President, Marketing

Dr. Karolina Urban, PhD
Executive Vice President, Medical &
Scientific Affairs

Board of Directors

Aras Azadian
Founder and CEO

Eileen McCormack
Independent Director

John McVicar
Independent Director

Giancarlo Davila Char
Director

Paul Fornazzari
Director



3.3 Corporate Highlights

- **Scale-up and internalization stage** with 4 business pillars
- **Diversified** - scalable and high margin revenue streams focused on intellectual property
- **Addressing a global market opportunity** with medical and pharmaceutical cannabinoid-based products
- **30+ commercial SKUs** and first approved indication specific pharmaceutical
- **Vertical integration** - low-cost, organic and sustainable supply chain



AVICANNA™





AVICANNA™

Thank You